- Email: [email protected]
Clear edge forms indian JV
Filtration Industry Analyst
NEWS/EXCHANGE RATES
Continued from page 1 “The acquisition of AFS compliments our existing aerospace filtration business well,” said Donaldson’s Lowell Schwab, senior vice president, Engine Systems and Parts. “Donaldson and AFS have already worked jointly over the last year to apply our media technology to AFS’s military and commercial aircraft systems. The acquisition of AFS allows us to further combine our filtration and manufacturing capabilities with AFS’s strong market position.”
CALGON CARBON DELAYS RELEASE OF 2006 RESULTS Calgon Carbon Corp says that it will delay the release of its results for the fourth quarter and year ended 31 December 2006, due to a pending comment letter from the Securities and Exchange Commission (SEC). The comment letter was issued as part of the SEC process to periodically review company filings. The company is responding to the comment letter in accordance with the standard process established by the SEC. Calgon Carbon has not scheduled a date for the release of fourth quarter and year-end results. The company will make an announcement when a date has been selected.
CLEAR EDGE FORMS INDIAN JV Clear Edge has established Clear Edge India, a joint venture with its former Indian agents Filfab and Tecfab India, located in a new factory in Jaipur, Rajasthan. The 8500 sq ft factory will manufacture the company’s normal range of screen and filter products and resell heavier
16
March 2007
process products for markets in the Indian region. Although relatively small at present, the Indian market is set to grow significantly in the wake of growth in China, increasing domestic demand and the progressive easing of regulation, says Clear Edge. Market sectors such as alumina, iron ore, fertiliser, pharmaceutical and chemical are of special interest – along with emerging demand for waste water treatment products. The company’s existing business activities were transferred to the new facility in November 2006.
major investments for our future and are critical to our continued success of supporting our global customers locally,” said Bill Cook, chairman, president, and CEO of Donaldson. “We are confident that our customers will benefit from these investments and our ongoing commitment to providing value-added filtration products.”
EXCHANGE RATES AGAINST THE US DOLLAR Date: 1.3.2007
DONALDSON EXPANDS GLOBAL DISTRIBUTION CAPACITY
COUNTRY Australia
Donaldson Co has added four distribution centres in Belgium, Indiana, South Africa and Mexico. The new 230 000 sq ft facility in Brugge, Belgium is enhanced by state of the art systems that allow for lean distribution services. Donaldson began shipping out of the Belgian centre in November 2006. The expanded Rensselaer, Indiana facility is Donaldson’s largest US distribution centre. The Indiana location has been extended by 50% to 600 000 sq ft, which will address the growing demand for replacement parts from US and Canadian customers. Donaldson’s new Johannesburg, South Africa facility opened in September 2006. This 90 000 sq ft facility was built to support customers in South Africa and sub-Saharan Africa. A new 72 000 sq ft distribution centre opened in Aguascalientes, Mexico in November last year. This facility will support customers in Mexico and Latin America. “These new and expanded distribution centres represent
RATE A$1.28
Austria
0.76
Belgium
0.76
Canada
C$1.18
China Denmark
RMB¥7.75 DKr5.65
Finland
0.76
France
0.76
Germany
0.76
India
Rs44.11
Italy
0.76
Japan
¥116.61
Malaysia
Rt3.51
Netherlands
0.76
Norway Philippines Singapore
NKr6.17 Peso48.41 S$1.53
South Africa
R7.41
South Korea
Won941.30
Spain
0.76
Sweden
SKr7.04
Switzerland
SFr1.22
Taiwan
T$32.90
Thailand
Bt33.68
UK USA
£0.51 US$1.00
Editorial Office Elsevier Ltd PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Roisin Reidy Senior Production/Design Controller Lin Lucas Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
NEWS/EXCHANGE RATES
Continued from page 1 “The acquisition of AFS compliments our existing aerospace filtration business well,” said Donaldson’s Lowell Schwab, senior vice president, Engine Systems and Parts. “Donaldson and AFS have already worked jointly over the last year to apply our media technology to AFS’s military and commercial aircraft systems. The acquisition of AFS allows us to further combine our filtration and manufacturing capabilities with AFS’s strong market position.”
CALGON CARBON DELAYS RELEASE OF 2006 RESULTS Calgon Carbon Corp says that it will delay the release of its results for the fourth quarter and year ended 31 December 2006, due to a pending comment letter from the Securities and Exchange Commission (SEC). The comment letter was issued as part of the SEC process to periodically review company filings. The company is responding to the comment letter in accordance with the standard process established by the SEC. Calgon Carbon has not scheduled a date for the release of fourth quarter and year-end results. The company will make an announcement when a date has been selected.
CLEAR EDGE FORMS INDIAN JV Clear Edge has established Clear Edge India, a joint venture with its former Indian agents Filfab and Tecfab India, located in a new factory in Jaipur, Rajasthan. The 8500 sq ft factory will manufacture the company’s normal range of screen and filter products and resell heavier
16
March 2007
process products for markets in the Indian region. Although relatively small at present, the Indian market is set to grow significantly in the wake of growth in China, increasing domestic demand and the progressive easing of regulation, says Clear Edge. Market sectors such as alumina, iron ore, fertiliser, pharmaceutical and chemical are of special interest – along with emerging demand for waste water treatment products. The company’s existing business activities were transferred to the new facility in November 2006.
major investments for our future and are critical to our continued success of supporting our global customers locally,” said Bill Cook, chairman, president, and CEO of Donaldson. “We are confident that our customers will benefit from these investments and our ongoing commitment to providing value-added filtration products.”
EXCHANGE RATES AGAINST THE US DOLLAR Date: 1.3.2007
DONALDSON EXPANDS GLOBAL DISTRIBUTION CAPACITY
COUNTRY Australia
Donaldson Co has added four distribution centres in Belgium, Indiana, South Africa and Mexico. The new 230 000 sq ft facility in Brugge, Belgium is enhanced by state of the art systems that allow for lean distribution services. Donaldson began shipping out of the Belgian centre in November 2006. The expanded Rensselaer, Indiana facility is Donaldson’s largest US distribution centre. The Indiana location has been extended by 50% to 600 000 sq ft, which will address the growing demand for replacement parts from US and Canadian customers. Donaldson’s new Johannesburg, South Africa facility opened in September 2006. This 90 000 sq ft facility was built to support customers in South Africa and sub-Saharan Africa. A new 72 000 sq ft distribution centre opened in Aguascalientes, Mexico in November last year. This facility will support customers in Mexico and Latin America. “These new and expanded distribution centres represent
RATE A$1.28
Austria
0.76
Belgium
0.76
Canada
C$1.18
China Denmark
RMB¥7.75 DKr5.65
Finland
0.76
France
0.76
Germany
0.76
India
Rs44.11
Italy
0.76
Japan
¥116.61
Malaysia
Rt3.51
Netherlands
0.76
Norway Philippines Singapore
NKr6.17 Peso48.41 S$1.53
South Africa
R7.41
South Korea
Won941.30
Spain
0.76
Sweden
SKr7.04
Switzerland
SFr1.22
Taiwan
T$32.90
Thailand
Bt33.68
UK USA
£0.51 US$1.00
Editorial Office Elsevier Ltd PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Roisin Reidy Senior Production/Design Controller Lin Lucas Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.